Integrated DNA Technologies Expands Into Clinical Diagnostics with First In Vitro Diagnostic

Key Takeaways

• IDT launches Archer IVD kits for oncology NGS diagnostics
• Products use anchored multiplex PCR for DNA/RNA targeted sequencing
• Kits include color‑coded reagents, robot‑friendly design, parallel workflow
• Entry expands IDT’s NGS portfolio, addressing US/EU regulatory demand

Pulse Analysis

The clinical sequencing landscape has rapidly shifted toward next‑generation sequencing (NGS) as the backbone of precision oncology, yet many laboratories still grapple with fragmented workflows and regulatory uncertainty. Integrated DNA Technologies, a Danaher subsidiary known for high‑quality oligonucleotides, is leveraging that expertise to launch Archer FUSION Plex‑HT Dx and VARIANT Plex‑HT Dx as its first in‑vitro diagnostic (IVD) offerings. By entering the US and key European markets, IDT directly addresses a gap for FDA‑ and EU‑compliant kits that combine discovery‑grade performance with clinical‑grade consistency.

The new Archer kits are built on IDT’s anchored multiplex PCR (AMP™) chemistry, enabling simultaneous DNA‑ and RNA‑targeted sequencing from a single library prep. Color‑coded reagents, magnetic bead cleanup, and robot‑friendly formats reduce hands‑on time, while parallel processing steps allow labs to scale throughput without sacrificing accuracy. This streamlined workflow translates into faster turnaround times for detecting gene fusions, point mutations, and complex variants—critical biomarkers that guide treatment decisions in solid tumors and hematologic malignancies.

Strategically, the launch expands IDT’s NGS portfolio beyond research reagents into the regulated diagnostic arena, positioning the company alongside established IVD players such as Illumina and Thermo Fisher. The move also signals Danaher’s broader ambition to capture more of the value chain in molecular diagnostics. With additional Archer IVD products slated for release, including assays for challenging sample types, IDT aims to create an end‑to‑end solution that simplifies the transition from biomarker discovery to clinical reporting, ultimately accelerating patient access to targeted therapies.